TOL - 25th May, 2021
Five critical factors for the rest of 2021
Morgan Stanley has just released its mid-year global update. This is an opportunity for our global team of more than 750 analysts, strategists and economists in 21 countries to recalibrate and align our views. This ensures consistency across countries and asset classes regarding our investment outlook.
Five key takeaways have implications for how we position our multi-asset model portfolios:
- A red-hot capital expenditure cycle will drive the next leg of the cycle;
- Policymakers will remain accommodative;
- Inflation is back but manageable;
- Covid-19 vaccination efforts, while uneven, are working; and
- Australia’s economy continues to gain momentum.
We remain positioned for growth in our multi-asset model portfolios but recognise the elevated near-term risk of volatility. We favour the quality and value factors in our equity positions. Interest rates should continue to face upside pressure. Corporate default risk is low, while alternative assets offer protection.
This report draws extensively from the mid-year outlook views published across Morgan Stanley's research department. We acknowledge their collective contribution.
#1 - The red hot capex cycle
The current economic cycle has been supported by government payments to households and businesses through sustaining consumption, which in turn has gained additional momentum as economies reopen. Morgan Stanley believes that we are moving to the mid-cycle of the current economic cycle. Global GDP has already exceeded pre-Covid-19 levels and is on pace to exceed long term trend growth by September. This creates a favourable economic backdrop that we believe will prompt corporations to invest and grow capacity. Morgan Stanley forecasts that global investment will be 121% of pre-Covid-19 levels by the end of 2022 - a level of investment reached 12 quarters from the bottom of the cycle versus 25 quarters after the GFC. We see global GDP growing 6.5% in 2021 followed by 4.8% in 2022, approximately 0.5% higher than consensus for both years.
Exhibit 1 - Global GDP to rise above the pre-COVID-19 path in 3Q21
#2 - Policymakers to remain accommodative
Morgan Stanley expects central banks and governments from major economies to remain highly accommodative. Central banks should only take small steps towards a tightening bias in 2021. For example, we expect the US Federal Reserve to only begin discussing the potential for the end of quantitative easing at its September meeting. The uneven rollout of the Covid-19 vaccine across the world creates enough uncertainty for central banks to retain their loose monetary conditions for fear of impacting the economic recovery. In a similar vein, governments from major economies which have unwritten private sector losses would be reluctant to remove support for a similar reason. Fiscal policy, which is currently at levels unseen outside of war years, should also remain elevated. We also believe that the COVID-19 recession has had a disproportionately more significant impact on lower-income households such that policymakers should err on the side of caution.
#3 - Inflation is rising but manageable
US inflation is currently the primary focus of markets. This is because US inflation impacts the US Federal Reserve's setting for the Federal Funds Rate, which is the key policy rate driving global markets. The US Federal Reserve has an inflation target for Core PCE (Personal Consumption Expenditure) of 2%. Core PCE has not held above 2% since the mid-1990s other than for a few years just prior to the GFC. However, Morgan Stanley believes Core PCE will finally exceed 2% on a sustained basis. Core PCE should peak at 2.7% in the short term, which generally would be a strong sign of overheating. However it is important to note that the Covid-19 recession distorts comparisons versus last year - for example, the price of West Texas Intermediate crude oil fell to -US$37 a barrel at one point. However, after this short period of elevated inflation we are not concerned regarding inflationary pressures per se given higher prices are a natural by-product of a normal economic cycle. That said, Morgan Stanley would reassess this position if Core PCE exceeded 2.5% before June 2022. At this level, we think this could put pressure on the US Federal Reserve to increase the Federal Funds Rate at a faster rate and bring the end of the cycle forward.
Exhibit 2 - Large Swings in Inflation Data Expected
Source: Bureau of Economic Analysis, Morgan Stanley Research
#4 - The vaccination drive is working
COVID-19 vaccination efforts are generally accelerating in Developed Markets but lagging in Emerging Markets. Unfortunately, Australia falls more into the latter group regarding vaccination progress. The evidence so far is the deployment of a variety of vaccines globally are stemming the tide of new infections and allowing economies to open more broadly. The most significant risk to our forecasts is the rise of COVID-19 variants. The slower deployment of vaccines in Emerging Markets might allow more variants to emerge which could become resistant to the current vaccines available. Moderna has shown from early test results that its booster shots are effective against known variants, but this remains far from certain. Our base case assumes no further significant lockdowns at a global level.
#5 - Australia is doing just fine
Morgan Stanley’s local economist and strategist (Chris Read and Chris Nicol) did not make significant changes to their forecasts as they had already incorporated a healthy recovery into their projections. However, they did acknowledge that the slower border reopening will negatively impact growth which saw GDP growth for 2022 revised down to 3.5% from 3.7% - although still keeps it above Morgan Stanley’s long term growth rate. The macroeconomic scenario in Australia is similar to the global narrative, with corporate spending poised to surge (corporate sentiment is at a ~25 year high) and inflation on the rise. Inflationary pressures are not as pronounced here in light of the stronger AUD, which means Morgan Stanley only sees inflation exceeding 2% towards the end of 2022.
Exhibit 3 – GDP Forecasts
Source: Bloomberg, RBA, Morgan Stanley Research
Positioning
What does all this mean for investors?
On a 12 month view, we expect markets to be generally higher. However, at the moment, we observe bear market conditions in the most speculative corners of the market, which historically does not bode well for risk assets. Our Chief US Strategist Mike Wilson believes a 10-20% de-rating in the S&P 500 P/E is entirely plausible, which is a generally conservative stance. In light of this "higher eventually but through a rocky valley" view, we believe the right action currently is to continue rotating within portfolios.
Within Equities, we recommend rotating towards securities with Value and Quality factor characteristics ((Vanguard All-World ex-US Shares Index ETF (ASX: VEU) and VanEck Vectors MSCI World ex Australia Quality ETF (ASX: QUAL). For Fixed Income, we continue to pursue a barbell with an allocation to high quality, long-duration government bonds for protection along with low-duration sub-investment grade credit for income (BetaShares Active Australian Hybrids Fund (ASX: HBRD).
Rising interest rates are still a challenge for Fixed Income securities (in particular government bonds). This is because, on our forecasts, higher-quality securities face negative 12 month total returns as their interest payments are insufficient to offset the capital loss from rising rates. This is the critical challenge facing multi-asset investors - how do you add defensive positions to your portfolio which have positive expected returns. One way is to invest into defensive alternative assets which do not move based on the direction of interest rates but rather position for changes in the internal dynamics of the fixed income market. In our opinion, this is an area where you need an actively managed fund.
Speak to your Morgan Stanley Financial Adviser and ask for direct shares and other ETFs and Managed Funds on our Focus List which align with our positioning views.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Nathan Lim is the Chief Investment Officer at Lonsec Holdings. He is responsible for building and managing Lonsec’s suite of investment solutions, devising strategies for growth and acting as the liaison with the market. Nathan has industry-recognised expertise, having won multiple awards for portfolio management and fund selection in both conventional and Responsible Investment categories.
........
The information and opinions in Morgan Stanley Wealth Management Research were prepared by Morgan Stanley Wealth Management Australia Pty Ltd (ABN 19 009 145 555, holder of Australian Financial Services License No. 240813) ("Morgan Stanley Wealth Management"), and Morgan Stanley Wealth Management takes responsibility for the production of this report. Morgan Stanley Wealth Management’s Research Department produces and distributes research products for clients of Morgan Stanley Wealth Management.
This Morgan Stanley Wealth Management Research is disseminated and available only in Australia.
For important disclosures (including copies of historical disclosures) regarding the securities and/or companies that are the subject of this Morgan Stanley Wealth Management Research product, please contact Morgan Stanley Wealth Management Research, Level 26 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Attention: Research Management. In addition, the same important disclosures, with the exception of the historical disclosures, are contained on the Firm's disclosure website: https://www.morganstanley.com/online/researchdisclosures Historical disclosures will be provided upon request back to June 1, 2009.
In addition, please contact us if you require Morgan Stanley Wealth Management Research model portfolio performance figures for previous periods.
Global Research Conflict Management Policy
Morgan Stanley Wealth Management has a Conflict Management policy available at:
https://www.morganstanley.com/online/researchconflictpolicies
Morgan Stanley & Co. LLC Stock Rating System & Definitions
For an explanation of Morgan Stanley's Stock Rating system and definitions, please refer to Morgan Stanley Wealth Management’s disclosure
website: https://www.morganstanley.com/online/researchdisclosures
Hybrid and Convertible Securities Rating System and Definitions
The value of hybrid and convertible securities can be impacted by a number of events including but not limited to movements in credit spreads, secondary market liquidity, and relative attractiveness of hybrid returns versus other asset classes. Significant event risk can also impact the value of hybrid and convertible securities. These include, but are not limited to credit adjustment by rating agencies, underlying entity fundamentals, changes in the tax and or regulatory environment, solvency issues surrounding the underlying entity and changes to the duration or maturity date. For a large number of investment grade securities, the rights to redeem, convert, change, and/or extend the terms lie with the issuer and not the holder of the security. Morgan Stanley Wealth Management cannot make an assessment on potential changes to terms until they have been announced by the issuer. Neither the capital value nor the distribution income of hybrid or convertible securities is guaranteed. In an event of default, hybrid securities may rank ahead of equity holders but behind debt holders in the winding up of an entity. For full terms & conditions of each hybrid or convertible security, including specific risks related to each security, refer to the prospectus or product disclosure statement available from your Financial Adviser. Morgan Stanley Wealth Management Research does not necessarily cover the underlying equity securities for hybrid and convertible securities mentioned in this report.
Investment Risk Rating: Morgan Stanley Wealth Management’s hybrids and convertibles risk ratings assess the risk of each security based on a number of quantitative and qualitative factors, including the financial strength of the issuer, debt/equity ratio of the issuer, interest cover of the issuer, the issuer’s ability to pay distributions, conversion risk, dilution risk of conversion into equity, and duration risk. Risk ratings assess both the risk of the issuer and the specific risk of the actual security. An issue can be rated high risk for example, despite the issuer being of sound financial health, due to security specific terms which are security holder ‘unfriendly’, or there is a high degree of uncertainty (and therefore “redemption value”) on the exit and/or conversion conditions.
Each security will then be given one of four ratings:
Low Risk – a security is backed by an entity that has strong capacity to meet its financial obligations and commitments. The risk of the entity missing a distribution payment is considered low.
Medium Risk – a security is backed by an entity that exhibits adequate protection parameters, however, adverse economic conditions or changes in circumstances could lead to a weakened capacity of the entity to meet its financial obligations.
High Risk – a security is backed by an entity that is more vulnerable to adverse economic conditions which may lead to distributions being lowered or cancelled. A security may also be considered High Risk when the outcomes surrounding the maturity date are largely unknown.
Speculative Risk – a security is backed by an entity that is highly vulnerable to adverse economic conditions. An entity may also be showing signs of financial stress. There is a high degree of uncertainty surrounding the entity’s ability to make a regular distribution payment.
The research analysts or strategists principally responsible for the preparation of Morgan Stanley Wealth Management Research have received compensation based upon various factors, including quality of research, investor client feedback, competitive factors, and firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues). Research analysts' or strategists' compensation is not linked to the profitability or revenues of particular capital markets transactions performed by Morgan Stanley Wealth Management or the profitability or revenues of particular fixed income trading desks. Morgan Stanley Wealth Management and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Wealth Management Research. Morgan Stanley Wealth Management and/or its affiliates sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Wealth Management Research on a principal basis. This communication has been prepared solely for information purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The material contained herein is not intended to constitute investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To the extent this communication is deemed to contain any general financial advice, such advice is prepared without taking account your objectives, financial situation or needs and because of this, you should, before acting on the general advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If the advice relates to the acquisition of a particular financial product for which a product disclosure statement or other disclosure document (‘offer document’) is available, you should obtain the offer document relating to the particular product and consider it before making any decision whether to acquire the product. Morgan Stanley Wealth Management recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a Financial Adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Wealth Management Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.
Morgan Stanley Smith Barney LLC, its affiliates and Morgan Stanley Financial Advisers do not provide legal or tax advice. Each client should always consult his/her personal tax and/or legal adviser for information concerning his/her individual situation and to learn about any potential tax or other implications that may result from acting on a particular recommendation. Morgan Stanley Wealth Management Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The important disclosures contained on the Firm's disclosure website at: https://www.morganstanley.com/online/researchdisclosures list all companies mentioned where Morgan Stanley Wealth Management or Morgan Stanley & Co. LLC owns 1% or more of a class of common equity securities of the securities/instruments of companies. Morgan Stanley Wealth Management or its affiliates may trade securities/instruments or derivatives of securities/instruments in ways different from those discussed in Morgan Stanley Wealth Management Research.
Employees of Morgan Stanley Wealth Management not involved in the preparation of Morgan Stanley Wealth Management Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Wealth Management Research. Morgan Stanley Wealth Management Research is based on public information. Morgan Stanley Wealth Management makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Wealth Management Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Wealth Management Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley Wealth Management business areas, including investment banking personnel.
The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realised. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. Morgan Stanley Wealth Management and its affiliates may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The trademarks and service marks contained in Morgan Stanley Wealth Management Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.
Morgan Stanley Wealth Management Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley Wealth Management.
Morgan Stanley Wealth Management Research is disseminated and available primarily electronically, and, in some cases, in printed form.
This report was prepared solely upon information generally available to the public. No representation is made that it is accurate and complete.
Additional information on recommended securities/instruments is available on request.
© 2021 Morgan Stanley Wealth Management Australia Pty Ltd
4 topics
3 stocks mentioned
Nathan Lim is the Chief Investment Officer at Lonsec Holdings. He is responsible for building and managing Lonsec’s suite of investment solutions, devising strategies for growth and acting as the liaison with the market. Nathan has...
Expertise
Nathan Lim is the Chief Investment Officer at Lonsec Holdings. He is responsible for building and managing Lonsec’s suite of investment solutions, devising strategies for growth and acting as the liaison with the market. Nathan has...
Expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
The 7 zombie companies lurking on the ASX 300
Livewire Markets
Education
Warren Buffett’s 25 biggest mistakes – and 4 lessons they teach
Leithner & Company Ltd